Tests baricitinib to delay type 1 diabetes in people at high risk
Tests baricitinib against placebo in people at high risk of type 1 diabetes.
Plain-language title generated from the registry record
Registry title: A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Key facts
- Where
- Barakaldo, Esplugues de Llobregat, and Madrid, SpainSee the 3 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and adults aged 1 to 35 years who are at high risk of type 1 diabetes. It tests whether baricitinib can delay the start of clinical type 1 diabetes.
- Age
- 1 year to 35 years
- Sex
- All sexes can join.
- Disease stage
- Stage 1b or Stage 2 type 1 diabetes, with at least two diabetes-related autoantibodies.
- Biomarker or test result
- At least two diabetes-related autoantibodies, documented before and also at screening or prescreening.
Main reasons for not taking part
- Any other type of diabetes
- Uncontrolled high blood pressure
- Heart attack, heart disease, stroke or heart failure
- History or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
- Current or recent clinically serious infection
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 35 years old?
Source: NCT07222137, who can take part
Where in Spain
- Hospital Universitario de CrucesBarakaldo, SpainTaking people
- Hospital Sant Joan De Deu BarcelonaEsplugues de Llobregat, SpainTaking people
- Hospital Universitario Ramón y CajalMadrid, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07222137EU 2025-521797-34-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.Read full original descriptionShow less
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Inclusion: Have a history of at least one documented occasion of at least two diabetes-related autoantibodies, AND one occasion of at least two diabetes-related autoantibodies obtained at screening or prescreening; Have Stage 1b or Stage 2 type 1 diabetes; Have a body weight of ≥8 kilograms (kg) (18 pounds) at screening.
Exclusion: Have any other type of diabetes; Have had a heart attack, heart disease, stroke, or heart failure; Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy; Have a current or recent clinically serious infection; Have uncontrolled high blood pressure.